Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials

Daniel H. Li, James B. Whitmore, Wentian Guo, Yuan Ji

Type: Article

Publication Date: 2016-10-15

Citations: 51

DOI: https://doi.org/10.1158/1078-0432.ccr-16-1125

View Publication

Locations

Clinical Cancer Research - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+	Data from Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials	2023	Daniel H. Li James B. Whitmore Wentian Guo Yuan Ji
+	Data from Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials	2023	Daniel H. Li James B. Whitmore Wentian Guo Yuan Ji
+	Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology	2020	Xiaolei Lin Yuan Ji
+	TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy	2020	Pin Li Rachael Liu Jianchang Lin Yuan Ji
+	The joint i3+3 (Ji3+3) design for phase I / II adoptive cell therapy clinical trials.	2020	Yuan Ji
+ PDF Chat	Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology	2024	Hao Sun Hsin‐Yu Lin Jieqi Tu Revathi Ananthakrishnan Eunhee Kim
+	Abstract 423: Toxicity and efficacy probability intervals design for phase I dose-finding in oncology trials	2016	Daniel H. Li Jim Whitmore Yuan Ji
+	uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials	2021	Haolun Shi Jiguo Cao Ying Yuan Ruitao Lin
+ PDF Chat	BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies	2020	Ruitao Lin Yanhong Zhou Fangrong Yan Daniel Li Ying Yuan
+ PDF Chat	Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2018	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren
+	Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials	2020	Jun Yin Ying Yuan
+	STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials	2017	Ruitao Lin Guosheng Yin
+ PDF Chat	Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding	2017	Fangrong Yan Peter F. Thall K.H. Lu Mark R. Gilbert Ying Yuan
+	Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity	2021	Zichun Xu Xiaolei Lin
+	Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies	2024	Yong Zang Beibei Guo Yingjie Qiu Hao Liu Mateusz Opyrchal Xiongbin Lu
+	Interval design to identify the optimal biological dose for immunotherapy	2022	Yeonhee Park
+	Data from Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2023	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren
+	Data from Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2023	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren
+	Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study	2023	Yusuke Yamaguchi Kentaro Takeda Satoshi Yoshida Kazushi Maruo
+	A Utility-Based Bayesian Phase I–II Design for Immunotherapy Trials with Progression-Free Survival End Point	2018	Beibei Guo Yeonhee Park Suyu Liu

Works That Cite This (40)

Action	Title	Year	Authors
+	A Likelihood Perspective on Dose‐Finding Study Designs in Oncology	2024	Zhiwei Zhang
+	uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials	2021	Haolun Shi Jiguo Cao Ying Yuan Ruitao Lin
+	Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs	2023	Ran Li Kentaro Takeda Alan Rong
+ PDF Chat	ATLCEP: A New Integrated Design that Encompasses the Safety and Efficacy Objectives of Phase I/II Trials	2017	Revathi Ananthakrishnan Stephanie Green Mark P. J. L. Chang Gheorghe Doros Joseph M. Massaro Daniel Li Michael P. LaValley
+ PDF Chat	Overview of model-assisted design for phase I dose-finding trials in oncology	2022	Koichi Hashizume Kentaro Takeda Hiroyuki Sato Akihiro Hirakawa Takashi Sozu
+	A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy	2023	Dapeng Zhang Jin Xu
+	A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs	2022	Chen Li Hongying Sun Cheng Cheng Li Tang Haitao Pan
+	A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology	2024	Jun Zhang Kentaro Takeda Masato Takeuchi Kanji Komatsu Jing Zhu Yusuke Yamaguchi
+	Computational Advancements in Cancer Combination Therapy Prediction	2023	Victoria L. Flanary Jennifer L. Fisher Elizabeth J. Wilk Timothy C. Howton Brittany N. Lasseigne
+ PDF Chat	BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies	2020	Ruitao Lin Yanhong Zhou Fangrong Yan Daniel Li Ying Yuan

Works Cited by This (13)

Action	Title	Year	Authors
+ PDF Chat	Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials	2013	Yuan Ji Sue-Jane Wang
+ PDF Chat	A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents	2013	Chunyan Cai Ying Yuan Yuan Ji
+	Design and Analysis of Phase I Clinical Trials	1989	Barry E. Storer
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher
+ PDF Chat	Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes	2012	Peter F. Thall Hoang Q. Nguyen
+	An integrated dose-finding tool for phase I trials in oncology	2015	Shengjie Yang Sue‐Jane Wang Yuan Ji
+ PDF Chat	A modified toxicity probability interval method for dose-finding trials	2010	Yuan Ji Ping Liu Yisheng Li B. Nebiyou Bekele
+	Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs	2004	Peter F. Thall John D. Cook
+ PDF Chat	Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity	2014	Juhee Lee Peter F. Thall Yuan Ji Peter Müller
+	Dose-finding in phase I clinical trials based on toxicity probability intervals	2007	Yuan Ji Yisheng Li B. Nebiyou Bekele